Immuno-oncology (IO) market – harnessing the immune system to fight cancer. The IO market was worth c.$7.4bn in 2016 – an increase of 159% over 2015 and driven by five products, the first of which was introduced in 2011. With the impending launch of AstraZeneca's Imfinzi for second-line bladder cancer and potentially first-line Stage 3 NSCLC later in the year, we forecast this class of compounds to grow to c.$18.1bn in 2018. These products (Keytruda, Opdivo, Imfinzi etc) represent
30 May 2017
Rude Health
Bioventix Plc (BVXP:LON), 4,600 | Byotrol plc (BYOT:LON), 0.4 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.1 | OptiBiotix Health PLC (OPTI:LON), 25.5 | SDI Group plc (SDI:LON), 71.0 | Tristel Plc (TSTL:LON), 470
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health
Bioventix Plc (BVXP:LON), 4,600 | Byotrol plc (BYOT:LON), 0.4 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.1 | OptiBiotix Health PLC (OPTI:LON), 25.5 | SDI Group plc (SDI:LON), 71.0 | Tristel Plc (TSTL:LON), 470
- Published:
30 May 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
32
Immuno-oncology (IO) market – harnessing the immune system to fight cancer. The IO market was worth c.$7.4bn in 2016 – an increase of 159% over 2015 and driven by five products, the first of which was introduced in 2011. With the impending launch of AstraZeneca's Imfinzi for second-line bladder cancer and potentially first-line Stage 3 NSCLC later in the year, we forecast this class of compounds to grow to c.$18.1bn in 2018. These products (Keytruda, Opdivo, Imfinzi etc) represent